Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
AffiliationSleep Research Laboratory, St. Vincent's University Hospital, Dublin, Ireland.
Adrenergic beta-Agonists/*administration & dosage
Albuterol/administration & dosage/*analogs & derivatives
Bronchodilator Agents/*administration & dosage
Forced Expiratory Volume
Lung Volume Measurements
Pulmonary Diffusing Capacity
Pulmonary Disease, Chronic Obstructive/*blood/drug therapy/physiopathology
MetadataShow full item record
CitationRespiration. 2010;79(6):475-81. Epub 2009 Aug 14.
JournalRespiration; international review of thoracic diseases
AbstractBACKGROUND: Sleep is associated with important adverse effects in patients with chronic obstructive pulmonary disease (COPD), such as disturbed sleep quality and gas exchange, including hypoxemia and hypercapnia. The effects of inhaled long-acting beta(2)-agonist therapy (LABA) on these disturbances are unclear. OBJECTIVES: The aim of the study was to assess the effect of inhaled salmeterol on nocturnal sleeping arterial oxygen saturation (SaO(2)) and sleep quality. METHODS: In a randomized, double-blind, placebo-controlled, crossover study of moderate/severe stable COPD patients, we compared the effects of 4 weeks of treatment with salmeterol 50 microg b.d. and matching placebo on sleeping SaO(2) and sleep quality. Overnight polysomnography (PSG) was performed at baseline, and after 4 and 8 weeks in addition to detailed pulmonary function testing. Of 15 patients included, 12 completed the trial (median age 69 years, forced expiratory volume in 1 s, FEV(1): 39%). RESULTS: Both mean SaO(2) [salmeterol vs. placebo: 92.9% (91.2, 94.7) vs. 91.0% (88.9, 94.8); p = 0.016] and the percentage of sleep spent below 90% of SaO(2) [1.8% (0.0, 10.8) vs. 25.6% (0.5, 53.5); p = 0.005] improved significantly with salmeterol. Sleep quality was similar with both salmeterol and placebo on PSG. Static lung volumes, particularly trapped gas volume, tended to improve with salmeterol. CONCLUSION: We conclude that inhaled LABA therapy improves sleeping SaO(2) without significant change in sleep quality.
- [Effect of salmeterol in obstructive sleep apnea syndrome].
- Authors: Rasche K, Duchna HW, Orth M, Bauer TT, Lauer J, Podbregar D, Schultze-Werninghaus G
- Issue date: 1998 Jan
- Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
- Authors: Lindberg A, Szalai Z, Pullerits T, Radeczky E
- Issue date: 2007 Sep
- Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
- Authors: Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
- Issue date: 2005 Apr
- Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
- Authors: Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
- Issue date: 2005 Jun
- Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly chronic obstructive pulmonary disease patients.
- Authors: Mochizuki H, Nanjo Y, Takahashi H
- Issue date: 2013 Apr